diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12768diaendo-12768Research ArticleОбзорыReviewНизкий риск гипогликемии и высокая эффективность гликлазида МВ: результаты последних исследованийLow risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studieshttps://orcid.org/0000-0003-4929-1526КононенкоИ. В.KononenkoI. V.

Кононенко Ирина Владимировна, к.м.н., в.н.с.

117036 Москва, ул. Дм. Ульянова, д. 11

eLibrary SPIN 6528-7986

Irina V. Kononenko, MD, PhD, leading research associate

11 Dm. Ulyanova street, 117036 Moscow

eLibrary SPIN 6528-7986 

shakhtarina@bk.ruhttps://orcid.org/0000-0003-3885-8988СмирноваО. М.SmirnovaO. M.

Смирнова Ольга Михайловна, д.м.н., профессор, гл.н.с.

eLibrary SPIN: 9742-8875 

Москва

Olga M. Smirnova, MD, PhD, Professor, chief research associate

eLibrary SPIN: 9742-8875 

Moscow

dr_smr@mail.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202110082021244350356Copyright © Кононенко И.В., Смирнова О.М., 20212021Кононенко И.В., Смирнова О.М.Kononenko I.V., Smirnova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12768

Производные сульфонилмочевины по-прежнему занимают ведущее место в лечении сахарного диабета 2 типа во всем мире во многом благодаря своей высокой эффективности. Вместе с тем гетерогенность группы очевидна, прежде всего в отношении влияния препаратов на риск развития гипогликемических состояний. В обзоре приведены результаты новых исследований, в том числе исследования «Сравнительная эффективность гликлазида МВ и ситаглиптина в реальной практике в качестве препаратов 2-й линии после монотерапии метформином у пациентов с неконтролируемым сахарным диабетом 2 типа», и данные метаанализа 24 сахароснижающих препаратов для лечения сахарного диабета 2 типа, подтверждающие более высокую эффективность гликлазида модифицированного высвобождения (гликлазида МВ) по сравнению с ингибиторами дипептидилпептидазы 4, наряду с низким риском гипогликемических состояний. ­Результаты последних исследований, а также исследований ADVANCE и ADVANCE-ON позволяют говорить о безопасном применении гликлазида МВ в качестве препарата второй линии, особенно у пациентов с хронической болезнью почек.

Sulfonylureas are widely prescribed all over the world, mainly because of their high effectiveness. At the same time, the heterogeneity of the group is obvious, primarily in relation to the effect of drugs on the risk of developing hypoglycemic events. The review presents the results of new studies, including «Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes» and results of a model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes, confirming the higher efficacy of modified release gliclazide (gliclazide MB) compared to DPP-4, as well as a low risk of hypoglycemic conditions. The results of recent studies, as well as the results of the ADVANCE and ADVANCE-ON studies, suggest that gliclazide MB is safe to use as a second-line drug, especially in patients with chronic kidney disease.

сахарный диабет 2 типагликлазид модифицированного высвобожденияэффективностьбезопасностьгипогликемические состоянийРамаданtype 2 diabetes mellitusmodified release gliclazideefficacysafetyhypoglycemic eventsRamadanReferencesДедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. // Сахарный диабет. — 2018. — Т. 21. — №3. — С. 144-159. [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159. (In Russ.)]. doi: https://doi.org/10.14341/DM9686Bibliography:Brown JB, Conner C, Nichols GA. Secondary Failure of Metformin Monotherapy in Clinical Practice. Diabetes Care. 2010;33(3):501-506. doi: https://doi.org/10.2337/dc09-1749Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of carbohydrate metabolism and the structure of antihyperglycemic therapy according to the Federal Register of Diabetes Mellitus, status 2017 I.I. Dedov, M.V. Shestakova, O. K. Vikulova *, A.V. Zheleznyakova, M.A. Isakov. Diabetes mellitus 2018; 21 (3): 143-159Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi: https://doi.org/10.2337/dc14-2441Brown J. B., Conner C., Nichols G. Secondary Failure of Glycemic Control for Patients Adding Thiazolidinedione or Sulfonylurea Therapy to a Metformin Regimen. Diabetes Care 33: 501-506, 2010Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY. Endocr Pract. 2016;22(1):84-113. doi: https://doi.org/10.4158/EP151126.CS.Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.Khunti K, Wolden ML, Thorsted BL, et al. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417. doi: https://doi.org/10.2337/dc13-0331Garber A, Abrahamson M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Type 2 Diabetes Management Algorithm 2016. Endocr Pract. 2016; 22: 84-113.Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. Diabet Med. 2015;32(3):407-413. doi: https://doi.org/10.1111/dme.12592Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013 Nov; 36 (11): 3411-7. doi: 10.2337 / dc13-0331.Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007;24(4):350-358. doi: https://doi.org/10.1111/j.1464-5491.2007.02078.x.Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med 2015; 32: 407-413.Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):100. doi: https://doi.org/10.1186/s12933-015-0260-xCook MN, Girman CJ, Stein PP, Alexander CM: Initial monotherapy with either metformin or sulfonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007, 24: 350-358.Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577-1589. doi: https://doi.org/10.1056/NEJMoa0806470Sanjoy K Paul, Kerenaftali Klein, Brian L Thorsted, Michael L Wolden, Kamlesh Khunti. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015 Aug 7; 14: 100. doi: 10.1186 / s12933-015-0260-x.Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации (Вып. 9) // Сахарный диабет. — 2019. — Т. 22. — №S1. — С. 1-144. [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.)]. doi: https://doi.org/10.14341/DM221S1Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow-up of intensive glycemic control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-1589.Holman RR, Paul SK, Bethel MA, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(S1):S111-S124. doi: https://doi.org/10.2337/dc21-S009"Algorithms of specialized medical care for patients with diabetes mellitus" edited by I.I. Dedov, M, V. Shestakova, A. Yu. Mayorov, 9th edition, 2019.Datta-Nemdharry P, Thomson A, Beynon J, Donegan K. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales. Pharmacoepidemiol Drug Saf. 2017;26(2):127-135. doi: https://doi.org/10.1002/pds.4092Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes — 2021. American Diabetes Association Diabetes Care 2021 Jan; 44 (Supplement 1): S111-S124.https: //doi.org/10.2337/dc21-S009Khunti K, Godec TR, Medina J, et al. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes, Obes Metab. 2018;20(2):389-399. doi: https://doi.org/10.1111/dom.13083.Datta-Nemdharry P, Thomson A, Beynon J, Donegan K. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales. Pharmacoepidemiol Drug Saf 2017; 26: 127-35.Zaccardi F, Jacquot E, Cortese V, et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obes Metab. 2020;22(12):2417-2426. doi: https://doi.org/10.1111/dom.14169.Khunti K, Godec T. R., Medina J. et. al. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes Obes Metab. 2018; 20: 389-399.Maloney A, Rosenstock J, Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213-1223. doi: https://doi.org/10.1002/cpt.1307Francesco Zaccardi, Emmanuelle Jacquot ,, Viviana Cortese, Freya Tyrer MSc, Samuel Seidu, Melanie J. Davies, Kamlesh Khunti. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 1-10 DOI: 10.1111 / dom.1416.Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65(11):1132-1140. doi: https://doi.org/10.1111/j.1742-1241.2011.02797.xAlan Maloney, Julio Rosenstock, Vivian Fonseca. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clinical Pharmacology & therapeutics | Volume 105 Number 5 | MAY 2019.Aravind SR, Tayeb K Al, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237-1242. doi: https://doi.org/10.1185/03007995.2011.578245Al Sifri S., Basiounny A., Echtay A., Al Omari M. et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomized trial // Int. J. Clin. Pract. 2011. Vol. 65. P. 1132-1140. 34.Hassanein M, Al-Arouj M, Hamdy O, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017;126:303-316. doi: https://doi.org/10.1016/j.diabres.2017.03.003Aravind S.R., Tayeb K.A., Ismail S.B. et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study // Curr. Med. Res. Opin. 2011. Vol. 27. P. 1237-1242. doi: 10.1185 / 03007995.2011.578245.Nicolucci A, Charbonnel B, Gomes MB, et al. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. Diabetes, Obes Metab. 2019;21(11):2474-2485. doi: https://doi.org/10.1111/dom.13830Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017; 126: 303-16.Matthews DR. ADVANCE. Diabetes, Obes Metab. 2020;22(S2):3-4. doi: https://doi.org/10.1111/dom.14014Nicolucci A, Charbonnel B, Gomes MB, et al. Treatment patterns and associated factors in 14,668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study program. Diabetes Obes Metab. 2019; 21: 2474-2485. https://doi.org/10.1111/dom.13830.Not Available NA, Committee AM. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44(9):1118-1120. doi: https://doi.org/10.1007/s001250100612Matthews D.R. ADVANCE. Diabetes Obes Metab. 2020; 22 (suppl 2): ​​3-4. DOI: https://doi.org/10.1111/dom.14014.Инструкция по медицинскому применению препарата Диабетон МВ. [Instruktsiya po meditsinskomu primeneniyu preparata Diabeton MV]. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c7ca665a-12a9-44d6-a6f5-672069650494&t=. Ссылка активна на 18.05.2021.ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118–20.Instructions for medical use of the drughttp://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c7ca665a-12a9-44d6-a6f5-672069650494&t=. Ссылка активна на 18.05.2021Instructions for medical use of the drughttp://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c7ca665a-12a9-44d6-a6f5-672069650494&t=. Ссылка активна на 18.05.2021

The authors declare that there are no conflicts of interest present.